Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.76
APRI's Cash-to-Debt is ranked lower than
67% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. APRI: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
APRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.69 Max: No Debt
Current: 0.76
Equity-to-Asset -0.90
APRI's Equity-to-Asset is ranked lower than
99% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. APRI: -0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
APRI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.53  Med: 0.42 Max: 0.87
Current: -0.9
-1.53
0.87
Piotroski F-Score: 3
Altman Z-Score: -54.83
Beneish M-Score: -4.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -179.67
APRI's Operating Margin % is ranked lower than
92% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. APRI: -179.67 )
Ranked among companies with meaningful Operating Margin % only.
APRI' s Operating Margin % Range Over the Past 10 Years
Min: -739.13  Med: -435.78 Max: -86.86
Current: -179.67
-739.13
-86.86
Net Margin % -117.79
APRI's Net Margin % is ranked lower than
91% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. APRI: -117.79 )
Ranked among companies with meaningful Net Margin % only.
APRI' s Net Margin % Range Over the Past 10 Years
Min: -1077.44  Med: -466.82 Max: -86.81
Current: -117.79
-1077.44
-86.81
ROA % -111.66
APRI's ROA % is ranked lower than
97% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. APRI: -111.66 )
Ranked among companies with meaningful ROA % only.
APRI' s ROA % Range Over the Past 10 Years
Min: -217.31  Med: -108.22 Max: -48.36
Current: -111.66
-217.31
-48.36
ROC (Joel Greenblatt) % -1188.70
APRI's ROC (Joel Greenblatt) % is ranked lower than
92% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. APRI: -1188.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
APRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2232.26  Med: -373.91 Max: -67.95
Current: -1188.7
-2232.26
-67.95
3-Year Revenue Growth Rate -30.50
APRI's 3-Year Revenue Growth Rate is ranked lower than
93% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. APRI: -30.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
APRI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.45 Max: 104.4
Current: -30.5
0
104.4
3-Year EBITDA Growth Rate -11.50
APRI's 3-Year EBITDA Growth Rate is ranked lower than
82% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. APRI: -11.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
APRI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.3  Med: -14.7 Max: 49.5
Current: -11.5
-41.3
49.5
3-Year EPS without NRI Growth Rate -25.90
APRI's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. APRI: -25.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
APRI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: -14.6 Max: 78.4
Current: -25.9
-44.4
78.4
GuruFocus has detected 5 Warning Signs with Apricus Biosciences Inc $APRI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» APRI's 10-Y Financials

Financials (Next Earnings Date: 2017-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with APRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:CBICF, NAS:BNTC, OTCPK:IMLFF, OTCPK:TRLPF, OTCPK:KAYS, NAS:ARDM, OTCPK:PTLF, OTCPK:AOLS, NAS:SNOA, NAS:FCSC, NAS:PTX, NAS:MYOS, AMEX:IGC, OTCPK:PUFXF, OTCPK:RSPI, OTCPK:PVCT, OTCPK:ACUR, NAS:DCTH, OTCPK:ULUR, OTCPK:YBAO » details
Traded in other countries:NXEM.Germany,
Apricus Biosciences Inc is a pharmaceutical company. It develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States.

Apricus Biosciences Inc was incorporated in Nevada in 1987. It is a pharmaceutical company, that develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. Its products have been developed utilizing its NexACT proprietary permeation enhancement technology. Its initial approved product is Vitaros approved in Canada for the treatment of erectile dysfunction (ED) and its next in-line late stage product candidate is Femprox for the treatment of female sexual arousal disorder (FSAD). It has also filed for approval of Vitaros for the treatment of ED in Europe through the Decentralized Approval Process (DCP) and in Switzerland. Femprox has completed one Phase III clinical trial in China and the Company is developing a regulatory submission plan for additional clinical trials in the U.S., Canada and Europe. The Company operates in a single segment, through which it design and develop pharmaceutical products with NexACT platform. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant), a specialty biotech contract research organization (CRO) based in San Diego, California. It own an approximate total of 83 registered trademarks as well as 65 pending trademark applications and 5 allowed pending trademark applications. It owns registered trademarks for Vitaros, Femprox and NexACT in certain countries and territories.

Ratios

vs
industry
vs
history
Forward PE Ratio 10.22
APRI's Forward PE Ratio is ranked higher than
83% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.82 vs. APRI: 10.22 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PS Ratio 2.25
APRI's PS Ratio is ranked higher than
57% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. APRI: 2.25 )
Ranked among companies with meaningful PS Ratio only.
APRI' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 12.15 Max: 109.54
Current: 2.25
0.77
109.54
Current Ratio 0.57
APRI's Current Ratio is ranked lower than
96% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. APRI: 0.57 )
Ranked among companies with meaningful Current Ratio only.
APRI' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 2.11 Max: 85.68
Current: 0.57
0.12
85.68
Quick Ratio 0.51
APRI's Quick Ratio is ranked lower than
93% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. APRI: 0.51 )
Ranked among companies with meaningful Quick Ratio only.
APRI' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 2.11 Max: 85.68
Current: 0.51
0.12
85.68
Days Inventory 49.12
APRI's Days Inventory is ranked higher than
86% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. APRI: 49.12 )
Ranked among companies with meaningful Days Inventory only.
APRI' s Days Inventory Range Over the Past 10 Years
Min: 23.31  Med: 121.47 Max: 147.27
Current: 49.12
23.31
147.27
Days Sales Outstanding 18.08
APRI's Days Sales Outstanding is ranked higher than
92% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. APRI: 18.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
APRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.13  Med: 28.34 Max: 87.02
Current: 18.08
2.13
87.02
Days Payable 135.77
APRI's Days Payable is ranked higher than
82% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. APRI: 135.77 )
Ranked among companies with meaningful Days Payable only.
APRI' s Days Payable Range Over the Past 10 Years
Min: 128.46  Med: 206.66 Max: 625.49
Current: 135.77
128.46
625.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.00
APRI's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. APRI: -19.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
APRI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -62.3  Med: -26.3 Max: -9
Current: -19
-62.3
-9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.18
APRI's Price-to-Median-PS-Value is ranked higher than
97% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. APRI: 0.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
APRI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.39 Max: 701.47
Current: 0.18
0.12
701.47
Earnings Yield (Greenblatt) % -56.80
APRI's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. APRI: -56.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
APRI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -136.7  Med: 0 Max: 0
Current: -56.8
-136.7
0

More Statistics

Revenue (TTM) (Mil) $8.04
EPS (TTM) $ -2.02
Beta-0.66
Short Percentage of Float17.19%
52-Week Range $1.10 - 15.40
Shares Outstanding (Mil)7.73

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 8 15
EPS ($) -2.35 0.30
EPS without NRI ($) -2.35 0.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for APRI

Headlines

Articles On GuruFocus.com
CEO and CFO Buys Weekly Update May 29 2013 

More From Other Websites
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events Feb 09 2017
Apricus Biosciences Receives Positive Nasdaq Listing Determination Feb 09 2017
Apricus Biosciences Receives Positive Nasdaq Listing Determination Feb 09 2017
Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference Feb 08 2017
Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference Feb 08 2017
Thursday’s Top Biopharma Movers Jan 19 2017
Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico Jan 19 2017
How Erectile Dysfunction in Mexico Just Made One Micro-Cap Stock More Than Double Jan 18 2017
Wednesday’s Top Biopharma Winners Jan 18 2017
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in... Jan 18 2017
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in... Jan 18 2017
Latest Reports on Biocept and Apricus Biosciences as President Trump's Comments Put Pressure on Drug... Jan 13 2017
Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel Jan 03 2017
Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel Jan 03 2017
Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel Jan 03 2017
Apricus Launches Vitaros in Lebanon for Erectile Dysfunction Dec 28 2016
Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in... Dec 27 2016
Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in... Dec 27 2016
Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in... Dec 27 2016
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)